1
|
Liu J, Liang L. The association between thyroid and breast cancers: a bidirectional mendelian randomization study. Front Endocrinol (Lausanne) 2023; 14:1185497. [PMID: 37955011 PMCID: PMC10634417 DOI: 10.3389/fendo.2023.1185497] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Accepted: 10/09/2023] [Indexed: 11/14/2023] Open
Abstract
Background Thyroid and breast cancers are the two most frequent types of endocrine-related tumors among women worldwide, and their incidence is still on the rise. Observational studies have shown a relationship between thyroid and breast cancers. Nevertheless, many confounders predispose the results to interference. Accordingly, we performed a two-sample Mendelian randomization (MR) study to investigate the causal association between thyroid and breast cancers. Methods We acquired breast cancer data from the UK Biobank (13,879 breast cancer cases and 198,523 controls) and the Breast Cancer Association Consortium (BCAC; 122,977 breast cancer cases and 105,974 controls), and thyroid cancer data from FinnGen Biobank (989 thyroid cancer and 217,803 controls). Then, the multiplicative random effects inverse variance weighting (IVW), weight median (WM), and MR Egger methods were executed for MR analysis. Results Overall, IVW showed a causal effect of breast cancer on thyroid cancer using the BCAC dataset (odds ratio [OR] = 1.17; 95% confidence interval [CI] = 1.036-1.322; P = 0.011), and this relationship was also supported by the UK Biobank dataset (OR = 23.899; 95% CI = 2.331-245.003; P = 0.007), which showed that breast cancer patients were more likely to be diagnosed with thyroid cancer. On the whole, the reverse MR analysis did not show a causal effect of breast cancer on thyroid cancer. However, IVW showed a causal effect of thyroid cancer on estrogen receptor -negative breast cancer using the BCAC dataset (OR = 1.019; 95% CI = 1.001-1.038; P = 0.043), which suggested that people with thyroid cancer were more likely to develop breast cancer. Conclusions Breast cancer represents a possible risk factor for thyroid cancer and thyroid cancer also represents a possible risk factor for ER-negative breast cancer. Future studies using powerful genetic tools to determine the causal relationship between breast and thyroid cancers are required.
Collapse
Affiliation(s)
- Jinchi Liu
- Department of Oncology, The Sixth Affiliated Hospital of Guangxi Medical University, The First People’s Hospital of Yulin, Guangxi, China
- China Medical University, Shenyang, China
| | - Leifeng Liang
- Department of Oncology, The Sixth Affiliated Hospital of Guangxi Medical University, The First People’s Hospital of Yulin, Guangxi, China
| |
Collapse
|
2
|
Hou F, Cheng T, Yang CL, Sun XD, Yang ZX, Lv J, Liu C, Deng ZY. Risk prediction of second primary malignant tumor in primary differentiated thyroid cancer patients: a population-based study. J Cancer Res Clin Oncol 2023; 149:12379-12391. [PMID: 37436512 DOI: 10.1007/s00432-023-05135-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2023] [Accepted: 07/04/2023] [Indexed: 07/13/2023]
Abstract
PURPOSE To investigate the risk factors of second primary malignant tumor (SPMT) in patients with differentiated thyroid cancer (DTC) and establish a competing risk nomogram to predict the probability of SPMT occurrence. METHODS We retrieved data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with DTC between 2000 and 2019. The Fine and Gray subdistribution hazard model was employed to identify SPMT risk factors in the training set and develop a competing risk nomogram. Model evaluation was performed using area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA). RESULTS A total of 112,257 eligible patients were included in the study and randomized into a training set (n = 112,256) and a validation set (n = 33,678). The cumulative incidence rate of SPMT was 15% (n = 9528). Age, sex, race, tumor multifocality, and TNM stage were independent risk factors of SPMT. The calibration plots showed good agreement between the predicted and observed SPMT risks. The 10-year AUCs of the calibration plots were 70.2 (68.7-71.6) in the training set and 70.2 (68.7-71.5) in the validation set. Moreover, DCA showed that our proposed model resulted in higher net benefits within a defined range of risk thresholds. The cumulative incidence rate of SPMT differed among risk groups, classified according to nomogram risk scores. CONCLUSION The competing risk nomogram developed in this study exhibits high performance in predicting the occurrence of SPMT in patients with DTC. These findings may help clinicians identify patients at distinct levels of risk of SPMT and develop corresponding clinical management strategies.
Collapse
Affiliation(s)
- Fei Hou
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Ting Cheng
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Chang-Long Yang
- Gastric and Small Intestine Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Xiao-Dan Sun
- Department of Publicity, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Zhi-Xian Yang
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Juan Lv
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China
| | - Chao Liu
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China.
| | - Zhi-Yong Deng
- Department of Nuclear Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, 650118, Yunnan, China.
| |
Collapse
|
3
|
Patini R, Cordaro M, Marchesini D, Scilla F, Gioco G, Rupe C, D'Agostino MA, Lajolo C. Is Systemic Immunosuppression a Risk Factor for Oral Cancer? A Systematic Review and Meta-Analysis. Cancers (Basel) 2023; 15:3077. [PMID: 37370688 DOI: 10.3390/cancers15123077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 05/30/2023] [Accepted: 06/01/2023] [Indexed: 06/29/2023] Open
Abstract
Even if the relationship between immunosuppression and increased incidence of systemic cancers is well known, there is less awareness about the risk of developing oral cancer in immunosuppressed patients. The aim of this review was to evaluate the association between immunosuppression and the development of oral cancer. Two authors independently and, in duplicate, conducted a systematic literature review of international journals and electronic databases (MEDLINE via OVID, Scopus, and Web of Science) from their inception to 28 April 2023. The assessment of risk of bias and overall quality of evidence was performed using the Newcastle-Ottawa Scale and GRADE system. A total of 2843 articles was identified, of which 44 met the inclusion criteria and were included in either the qualitative or quantitative analysis. The methodological quality of the included studies was generally high or moderate. The quantitative analysis of the studies revealed that immunosuppression should be considered a risk factor for the development of oral cancer, with a percentage of increased risk ranging from 0.2% to 1% (95% CI: 0.2% to 1.4%). In conclusion, the results suggest that a constant and accurate follow-up should be reserved for all immunosuppressed patients as a crucial strategy to intercept lesions that have an increased potential to evolve into oral cancer.
Collapse
Affiliation(s)
- Romeo Patini
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Massimo Cordaro
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Denise Marchesini
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Francesco Scilla
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Gioele Gioco
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Cosimo Rupe
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Maria Antonietta D'Agostino
- Department of Geriatric and Orthopedic Sciences, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| | - Carlo Lajolo
- Department of Head, Neck and Sense Organs, School of Dentistry, Catholic University of Sacred Heart, Fondazione Policlinico Universitario "A. Gemelli"-IRCCS Rome, 00135 Rome, Italy
| |
Collapse
|
4
|
Bobde V, Helwatkar S, Raut W. Synchronous columnar cell variant of papillary thyroid carcinoma with invasive breast carcinoma. J Cancer Res Ther 2022; 18:S498-S500. [PMID: 36511015 DOI: 10.4103/jcrt.jcrt_1255_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Synchronous or metachronous associations of multiple malignancies are seen commonly in syndromic cases. Double malignancies with thyroid carcinomas are common with papillary thyroid carcinoma (PTC) than with other differentiated thyroid cancers. The presence of double malignancy should be ruled out before treatment as it may need different and multiple treatment modalities. We report a case of a columnar cell variant of PTC with invasive breast carcinoma in 56-year-old female patient. The columnar cell variant of PTC is rare and show inconspicous classical nuclear features of conventional PTC.
Collapse
Affiliation(s)
- Vedita Bobde
- Department of Pathology, Government Medical College, Nagpur, Maharashtra, India
| | - Satish Helwatkar
- Department of Pathology, Government Medical College, Nagpur, Maharashtra, India
| | - Waman Raut
- Department of Pathology, Government Medical College, Nagpur, Maharashtra, India
| |
Collapse
|
5
|
Kim M, Kim H, Park S, Joo J, Kim IJ, Kim BH. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study. Eur J Endocrinol 2022; 186:561-571. [PMID: 35286279 DOI: 10.1530/eje-21-1208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Accepted: 03/14/2022] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Thyroid cancer survivors have a high risk of second primary malignancies (SPMs). We aimed to evaluate the site-specific incidence, prognosis, and risk factors for metachronous SPMs following thyroid cancer. DESIGN A nationwide cohort study. METHODS This study included data from the Korea National Health Insurance Service (between 2002 and 2018). Exposure to diagnostic radiation was defined by the number of computed tomography (CT) and positron emission tomography-CT scans after the index date. A cumulative radioactive iodine (RAI) dose >100 mCi was considered high-dose RAI. RESULTS During the median 6 years of follow-up, among 291 640 patients, 13 083 (4.5%) developed SPMs. Thyroid cancer survivors had a 26% increased risk of SPMs compared with the general population (standardized incidence ratio: 1.26; 95% CI: 1.22-1.29). Furthermore, those with SPMs had a significantly poorer survival rate than those without SPMs (hazard ratio: 11.85; 95% CI: 11.21-12.54; P < 0.001). Significantly elevated risks were observed in myeloid leukemia and 13 solid cancer sites: lip, salivary gland, small intestine, larynx, lung, mediastinum and pleura, mesothelium, breast, corpus uteri, ovary, prostate, kidney, and bladder. Frequent diagnostic medical radiation exposure and high-dose RAI therapy were independent risk factors for several SPMs, including the cancer of salivary gland, lung, mediastinum and pleura, breast, kidney, and bladder, as well as myeloid leukemia. CONCLUSIONS Frequent diagnostic radiation exposure and high-dose RAI therapy are independent risk factors for SPM following thyroid cancer. Clinicians need to consider minimizing unnecessary diagnostic radiation exposure and administering a high dose RAI only when justified in patients with thyroid cancer.
Collapse
Affiliation(s)
- Mijin Kim
- Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Hyereen Kim
- Hyereen Kim's Internal Medicine Clinic, Yangsan, Korea
| | - Sojeong Park
- Data Science Team, Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - Jaeeun Joo
- Data Science Team, Hanmi Pharmaceuticals Co., Ltd., Seoul, Korea
| | - In Ju Kim
- Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| | - Bo Hyun Kim
- Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Busan, Korea
| |
Collapse
|
6
|
Si L, Feng Y, Wang Y, Zhong J, Sun Z, Li X, Sun Y. Clinical and pathological characteristics of multiple primary malignant neoplasms cases. Int J Clin Pract 2021; 75:e14663. [PMID: 34387916 DOI: 10.1111/ijcp.14663] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 07/26/2021] [Indexed: 01/02/2023] Open
Abstract
OBJECTIVES To investigate the clinical and pathological features of multiple primary malignant neoplasms (MPMNs) cases. METHODS The clinical data of 24 105 tumour patients admitted to Jiangsu Cancer Hospital in 2018 were retrospectively reviewed, and 270 patients with MPMNs were selected as the research subjects. Among them, 101 cases of synchronous carcinoma (SC) and 92 cases of metachronous carcinoma (MC) were divided into groups for statistical analysis. Univariate and multivariate cox regression analyses were conducted using SPSS 22.0 software. RESULTS Among 24 105 cases, there was a male-to-female ratio of 1.45:1. Compared with MC cases, SC patients have a higher proportion of male cases. Primary neoplasms in gastric cancer, head and neck cancer, oesophageal cancer and colon cancer occupied most cases in male MPMNs, while primary breast cancer ranked first in female MPMNs. In addition, the leading secondary neoplasms were duodenal carcinoma, lung cancer and male MPMNs and lung cancer in female MPMNs. As for SC MPMNs, primary neoplasms were occupied by lung cancer, gastric cancer and oesophageal cancer, while the secondary neoplasms were mostly consisted of oesophageal cancer and lung cancer. Finally, the MC MPMNs were mostly consisted of breast cancer and gastric cancer as primary neoplasms, while lung cancer and oesophageal cancer as secondary neoplasms. CONCLUSIONS Screening for primary cancer should be strengthened over the age of 50 years for male patients with gastric cancer or female patients with breast cancer to reduce or monitor the occurrence of MPMNs.
Collapse
Affiliation(s)
- Lixiang Si
- The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
| | - Yuxu Feng
- Department of Orthopaedics, Pukou Central Hospital, PuKou Branch Hospital of Jiangsu Province Hospital, Nanjing, People's Republic of China
| | - Yajing Wang
- The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
| | - Jie Zhong
- The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
| | - Zijian Sun
- The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, China
| | - Xiaoyou Li
- Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Yan Sun
- Department of Medical Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
7
|
Liu CY, Huang CS, Huang CC, Ku WC, Shih HY, Huang CJ. Co-Occurrence of Differentiated Thyroid Cancer and Second Primary Malignancy: Correlation with Expression Profiles of Mismatch Repair Protein and Cell Cycle Regulators. Cancers (Basel) 2021; 13:cancers13215486. [PMID: 34771648 PMCID: PMC8582561 DOI: 10.3390/cancers13215486] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Revised: 10/26/2021] [Accepted: 10/29/2021] [Indexed: 12/21/2022] Open
Abstract
Simple Summary Although the incidence of thyroid cancer is increasing, improvements in treatment have resulted in more patients being confirmed to have a second primary cancer. However, studies on potential biomarkers for predicting the risk of second primary malignancy are extremely limited. Therefore, our objective was to establish molecular biomarkers for the risk prediction of second primary malignancy using routinely collected formalin-fixed paraffin-embedded tissue specimens. Our results suggest that the deficient mismatch repair phenotype, the expression of pRb, and the lack of CDK4 or CDK6 are significantly associated with co-occurrence of nonthyroid malignancy. The predictive value of these immunohistochemical profiles for the co-occurrence of nonthyroid malignancy was also assessed. The combined evaluation of a four-biomarker signature model may provide the most important predictive innovation. Our study proposes the first tissue-based screening tool for risk stratification and further active surveillance in patients with thyroid cancer. Abstract Some patients with thyroid cancer develop a second primary cancer. Defining the characteristics of patients with double primary cancers (DPCs) is crucial and needs to be followed. In this study, we examine molecular profiles in DPC. We enrolled 71 patients who received thyroid cancer surgery, 26 with single thyroid cancer (STC), and 45 with DPC. A retrograde cohort was used to develop immunohistochemical expressions of mismatch repair (MMR) proteins and cell-cycle-related markers from tissue microarrays to produce an equation for predicting the occurrence of DPC. The multivariate logistic model of 67 randomly selected patients (24 with STC and 43 with DPC) identified that the expression of deficient MMR (dMMR) (odds ratio (OR), 10.34; 95% confidence interval (CI), 2.17–49.21) and pRb (OR, 62.71; 95% CI, 4.83–814.22) were significantly associated with a higher risk of DPC. In contrast, the expression of CDK4 (OR, 0.19; 95% CI, 0.04–0.99) and CDK6 (OR, 0.03; 95% CI, 0.002–0.44) was significantly associated with a lower risk of DPC. Collectively, dMMR, pRb, CDK4, and CDK6 have a sensitivity of 88.9% (95% CI, 75.1–95.8) and a specificity of 69.2% (95% CI, 48.1–84.9) for occurrence of DPC in all 71 patients. This is the first report to demonstrate the molecular differentiation of STC and DPC. Overall, the integral molecular profile performed excellent discrimination and denoted an exponential function to predict the probability of DPC.
Collapse
Affiliation(s)
- Chih-Yi Liu
- Division of Pathology, Sijhih Cathay General Hospital, New Taipei City 221, Taiwan;
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan;
| | - Ching-Shui Huang
- Division of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan; (C.-S.H.); (H.-Y.S.)
- School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
| | - Chi-Cheng Huang
- Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taipei 1121, Taiwan;
- School of Public Health, College of Public Health, National Taiwan University, Taipei 100, Taiwan
| | - Wei-Chi Ku
- School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 242, Taiwan;
| | - Hsing-Yu Shih
- Division of General Surgery, Department of Surgery, Cathay General Hospital, Taipei 106, Taiwan; (C.-S.H.); (H.-Y.S.)
| | - Chi-Jung Huang
- Department of Medical Research, Cathay General Hospital, Taipei 106, Taiwan
- Department of Biochemistry, National Defense Medical Center, Taipei 114, Taiwan
- Correspondence:
| |
Collapse
|
8
|
Piciu A, Mester A, Rusu G, Piciu D. Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals. Curr Radiopharm 2020; 14:85-91. [PMID: 32988358 DOI: 10.2174/1874471013666200928105151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 08/24/2020] [Accepted: 08/27/2020] [Indexed: 11/22/2022]
Abstract
Thyroid carcinoma represents a complex pathology that can still be considered a medical challenge, despite having a better prognosis and life expectancy than most other neoplasms; also the scenario of multiple malignancies involving thyroid cancer is nowadays a common reality. MATERIALS AND METHODS We reviewed the literature regarding the aggressive presentation of synchronous thyroid and breast cancer. In the current paper, we report the case of a 59 years-old woman, diagnosed with invasive ductal breast carcinoma and papillary thyroid carcinoma, presenting a natural history of both aggressive synchronous tumors. At the moment of hospitalization, the diagnosis was breast carcinoma with multiple secondary lesions, suggestive of lung and bone metastases, and nodular goiter. RESULTS Searching the literature in PUBMED with the terms "thyroid carcinoma and synchronous breast carcinoma, we found 86 studies; introducing the term "aggressive," the result included 4 studies, among which, none showed to be relevant to the terms aggressive and synchronous. A similar search was done in SCOPUS finding 92 documents and after introducing the term aggressive, the number of papers was 8, none including the literature on synchronous aggressive metastatic thyroid and breast carcinoma. A majority of imaging diagnostic tools were used in this particular medical case in order to ensure the best potential outcome. The final diagnosis was papillary thyroid carcinoma with lung and unusual multiple bone metastases and synchronous invasive ductal breast carcinoma with subcutaneous metastases. CONCLUSION The case illustrates the challenges in the correct assessment of oncologic patients, despite the advances in medical imaging and technologies and underlines the essential role of nuclear medicine procedures in the diagnostic and therapy protocols.
Collapse
Affiliation(s)
- Andra Piciu
- Department of Medical Oncology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Alexandru Mester
- Department of Oral Health, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - George Rusu
- Department of Endocrine Tumors and Nuclear Medicine Institute of Oncology Ion Chiricuta 400015 Cluj-- Napoca, Romania
| | - Doina Piciu
- Department of Endocrine Tumors and Nuclear Medicine Institute of Oncology Ion Chiricuta 400015 Cluj-- Napoca, Romania
| |
Collapse
|
9
|
Lin HT, Liu FC, Lin SF, Kuo CF, Chen YY, Yu HP. Familial Aggregation and Heritability of Nonmedullary Thyroid Cancer in an Asian Population: A Nationwide Cohort Study. J Clin Endocrinol Metab 2020; 105:5825279. [PMID: 32333767 DOI: 10.1210/clinem/dgaa191] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2020] [Accepted: 04/23/2020] [Indexed: 12/24/2022]
Abstract
PURPOSE The purpose of this work is to assess the extent of familial aggregation of nonmedullary thyroid cancer (NMTC) and the relative risks (RRs) of chronic thyroid diseases and common malignancies in first-degree relatives of NMTC patients. METHODS In the National Health Insurance Research database of Taiwan, all eligible individuals in 2016 were analyzed (n = 23 696 659) and the family structures of 38 686 patients diagnosed with NMTC between 1997 and 2016 were identified. The prevalence and RRs of NMTC, chronic thyroid diseases, and common malignancies in individuals with first-degree relatives with NMTC were examined. The accountability of heritability and environmental factors to NMTC susceptibility was estimated using the polygenic liability model. RESULTS The prevalence of NMTC was 0.16% in the general population and 0.64% in individuals with first-degree relatives with NMTC. Regarding affected relatives, the RR (95% CI) for NMTC was 20.12 (4.86-83.29) for twins, 6.43 (4.80-8.62) for siblings, 5.24 (4.55-6.03) for offspring, 5.07 (4.41-5.81) for parents, and 2.07 (1.53-2.81) for spouses. The estimated genetic, common environmental, and nonshared environmental contributions to NMTC were 28.0%, 14.3%, and 57.7%, respectively. A family history of NMTC was associated with higher risks of thyroid nodules (RR, 2.26; 95% CI, 2.18-2.35), Hashimoto thyroiditis (2.11; 1.89-2.36), Graves disease (1.49; 1.42-1.57), lung cancer (1.56; 1.32-1.85), and leukemia and lymphoma (1.24; 1.03-1.50). CONCLUSION Our findings demonstrate the importance of genetic and environmental contributions to NMTC susceptibility and highlight the coaggregation of chronic thyroid diseases and multiple malignancies with NMTC.
Collapse
Affiliation(s)
- Huan-Tang Lin
- Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Fu-Chao Liu
- Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
| | - Shu-Fu Lin
- Department of Endocrinology and Metabolism, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Chang-Fu Kuo
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- Office for Big Data Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Yu-Ying Chen
- Office for Big Data Research, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Huang-Ping Yu
- Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
- College of Medicine, Chang Gung University, Taoyuan, Taiwan
- Department of Anesthesiology, Xiamen Chang Gung Hospital, Xiamen, China
| |
Collapse
|
10
|
Polednik KM, Simpson MC, Adjei Boakye E, Mohammed KA, J Dombrowski J, Varvares MA, Osazuwa-Peters N. Radiation and Second Primary Thyroid Cancer Following Index Head and Neck Cancer. Laryngoscope 2018; 129:1014-1020. [PMID: 30208210 DOI: 10.1002/lary.27467] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
OBJECTIVES/HYPOTHESIS Radiation is thought to increase risk of developing second primary thyroid cancer (SPTC). This study estimated the rate of SPTC following index head and neck cancer (HNC) and determined whether radiation treatment among HNC survivors increased SPTC risk. STUDY DESIGN Retrospective data analysis. METHOD The Surveillance, Epidemiology, and End Results database (1975-2014) was queried for cases of index HNC (N = 127,563) that developed SPTC. Adjusted multivariable competing risk proportional hazards model tested risk of developing a SPTC following index HNC. Sensitivity analyses using proportional hazards models were also performed restricting data to patients who 1) received both radiation and chemotherapy and 2) radiation alone. RESULTS Only 0.2% of index HNC survivors (n = 229) developed SPTC, yielding a rate of 26.1 per 100,000 person-years. For every increasing year of age at diagnosis, patients were 3% less likely to develop an SPTC (adjusted hazard ratio [aHR] = 0.97, 95% CI: 0.96-0.98). Males were also less likely to develop an SPTC (aHR = 0.73, 95% CI: 0.55-0.96). Radiation (aHR = 0.92, 95% CI: 0.68-1.25), surgery (aHR = 0.79, 95% CI: 0.56-1.11), and chemotherapy (aHR = 1.13, 95% CI: 0.76-1.69) were not significantly associated with developing SPTC. The sensitivity models also did not find an association between treatment and risk of SPTC. CONCLUSIONS Rate of developing SPTC following index HNC was very low, and previous exposure to radiation did not significantly increase risk in our study population. More studies are needed to understand the increasing incidence of thyroid cancer across the United States. LEVEL OF EVIDENCE NA Laryngoscope, 129:1014-1020, 2019.
Collapse
Affiliation(s)
| | - Matthew C Simpson
- Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Eric Adjei Boakye
- Center for Health Outcomes Research, Saint Louis University, St. Louis, Missouri
| | - Kahee A Mohammed
- Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri.,Center for Health Outcomes Research, Saint Louis University, St. Louis, Missouri
| | - John J Dombrowski
- Department of Radiation Oncology, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Mark A Varvares
- Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts
| | - Nosayaba Osazuwa-Peters
- Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, Missouri.,Saint Louis University Cancer Center, St. Louis, Missouri.,Department of Epidemiology and Biostatistics, College for Public Health and Social Justice, Saint Louis University, St. Louis, Missouri, U.S.A
| |
Collapse
|
11
|
Al-Qahtani KH, Al-Asiri M, Tunio MA, Aljohani NJ, Bayoumi Y, Al-Hussain H, Maklad AM. Prevalence and treatment outcomes of second primary malignancies in Saudi patients with differentiated thyroid cancers. Saudi Med J 2016; 36:442-8. [PMID: 25828281 PMCID: PMC4404478 DOI: 10.15537/smj.2015.4.10341] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVES To evaluate the clinicopathologic features, and explore the treatment outcomes of synchronous, or metachronous second primary malignancies (SPM) in conjunction with differentiated thyroid cancers (DTC). METHODS This retrospective study was conducted on 823 DTC patients treated between 2000 and 2012 at 2 tertiary care hospitals (King Fahad Medical City and King Khalid University Hospital) in Riyadh, Kingdom of Saudi Arabia. Forty-one (5%) DTC patients were found to have SPM (61% metachronous and 39% synchronous). These patients with SPM were studied for clinicopathological features and treatment outcomes. RESULTS The patients with DTC and SPM were older (median age: 54.3 years) than those without SPM (median age: 43.2 years); p=0.04. The frequency of SPM was breast (51.2%), colon (12.2%), kidney (7.3%), astrocytoma (7.3%), parotid (7.3%), rectum (4.9%), lymphoma (4.9%), nasopharynx (2.4%), and stomach (2.4%). Median follow-up was 8.05 years. Ten-year disease free survival, and overall survival (OS) rates were lower in DTC patients with SPM (56.1% for 10-year survival, and 71.7% for OS) than without SPM (95.5% for 10-year survival, and 97.8% for OS); p=0.0001. Metachronous SPM had better 10-year disease free survival rates (60.2%) than synchronous SPM (45%). CONCLUSION The co-occurrence of SPM with DTC affects long-term disease free survival and OS rates.
Collapse
Affiliation(s)
- Khalid H Al-Qahtani
- Department of Otolaryngology-Head & Neck Surgery, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. E-mail.
| | | | | | | | | | | | | |
Collapse
|
12
|
Dong L, Gao M, Hao WJ, Zheng XQ, Li YG, Li XL, Yu Y. Case Report of Birt-Hogg-Dubé Syndrome: Germline Mutations of FLCN Detected in Patients With Renal Cancer and Thyroid Cancer. Medicine (Baltimore) 2016; 95:e3695. [PMID: 27258496 PMCID: PMC4900704 DOI: 10.1097/md.0000000000003695] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Birt-Hogg-Dubé (BHD) is a rare autosomal dominant inherited syndrome that is characterized by the presence of fibrofolliculomas and/or trichodiscomas, pulmonary cysts, spontaneous pneumothorax, and renal tumors. Here, the 2 patients we reported with renal cell carcinomas and dermatological features were suspected to be suffering from BHD syndrome. Blood samples of these patients were sent for whole exon sequencing performed by Sanger sequencing. Eight mutations, including 5 mutations, which were mapped in noncoding region, 1 synonymous mutation, and 2 missense mutations, were detected in the FLCN gene in both patients. The 2 missense mutations, predicted to be disease-causing mutation or affecting protein function by MutationTaster and SIFT, confirmed the diagnosis. In addition, the 2 patients were also affected with papillary thyroid cancer. Total thyroidectomy and prophylactic bilateral central lymph node dissection were performed for them and the BHD-2 also received lateral lymph node dissection. Pathology reports showed that the patients had lymph node metastasis in spite of small size of thyroid lesions.The 2 missense mutations, not reported previously, expand the mutation spectrum of FLCN gene associated with BHD syndrome. For the thyroid cancer patients with BHD syndrome, total thyroidectomy and prophylactic bilateral central lymph node dissection may be suitable and the neck ultrasound may benefit BHD patients and their family members.
Collapse
Affiliation(s)
- Li Dong
- From the Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, and Oncology Key Laboratory of Cancer Prevention and Therapy (LD, MG, W-JH, X-QZ, Y-GL, YY), Tianjin, China; and Department of Neuro-Oncology (X-LL), University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | | | | | | | | |
Collapse
|
13
|
Ikeda Y, Kiyotani K, Yew PY, Kato T, Tamura K, Yap KL, Nielsen SM, Mester JL, Eng C, Nakamura Y, Grogan RH. Germline PARP4 mutations in patients with primary thyroid and breast cancers. Endocr Relat Cancer 2016; 23:171-9. [PMID: 26699384 PMCID: PMC5152685 DOI: 10.1530/erc-15-0359] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/23/2015] [Indexed: 12/20/2022]
Abstract
Germline mutations in the PTEN gene, which cause Cowden syndrome, are known to be one of the genetic factors for primary thyroid and breast cancers; however, PTEN mutations are found in only a small subset of research participants with non-syndrome breast and thyroid cancers. In this study, we aimed to identify germline variants that may be related to genetic risk of primary thyroid and breast cancers. Genomic DNAs extracted from peripheral blood of 14 PTEN WT female research participants with primary thyroid and breast cancers were analyzed by whole-exome sequencing. Gene-based case-control association analysis using the information of 406 Europeans obtained from the 1000 Genomes Project database identified 34 genes possibly associated with the phenotype with P < 1.0 × 10(-3). Among them, rare variants in the PARP4 gene were detected at significant high frequency (odds ratio = 5.2; P = 1.0 × 10(-5)). The variants, G496V and T1170I, were found in six of the 14 study participants (43%) while their frequencies were only 0.5% in controls. Functional analysis using HCC1143 cell line showed that knockdown of PARP4 with siRNA significantly enhanced the cell proliferation, compared with the cells transfected with siControl (P = 0.02). Kaplan-Meier analysis using Gene Expression Omnibus (GEO), European Genome-phenome Archive (EGA) and The Cancer Genome Atlas (TCGA) datasets showed poor relapse-free survival (P < 0.001, Hazard ratio 1.27) and overall survival (P = 0.006, Hazard ratio 1.41) in a PARP4 low-expression group, suggesting that PARP4 may function as a tumor suppressor. In conclusion, we identified PARP4 as a possible susceptibility gene of primary thyroid and breast cancer.
Collapse
Affiliation(s)
- Yuji Ikeda
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Kazuma Kiyotani
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Poh Yin Yew
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Taigo Kato
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Kenji Tamura
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Kai Lee Yap
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Sarah M Nielsen
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Jessica L Mester
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Charis Eng
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Yusuke Nakamura
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| | - Raymon H Grogan
- Section of Hematology/OncologyDepartment of Medicine, The University of Chicago, Chicago, Illinois 60637, USAGenomic Medicine InstituteCleveland Clinic, Cleveland, Ohio 44195, USADepartment of Genetics and Genome SciencesComprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USAEndocrine Surgery Research ProgramSection of General Surgery, Department of Surgery, The University of Chicago, 5841 S Maryland Avenue, Chicago, Illinois 60637, USA
| |
Collapse
|
14
|
Lin CY, Lin CL, Huang WS, Kao CH. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study. J Nucl Med 2015; 57:685-90. [PMID: 26719377 DOI: 10.2967/jnumed.115.164830] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2015] [Accepted: 12/01/2015] [Indexed: 12/16/2022] Open
Abstract
UNLABELLED An increased risk of second primary malignancy after (131)I therapy has been reported. The objective of this study was to determine the risk of breast cancer in patients with thyroid cancer receiving or not receiving radioiodine treatment in Taiwan. METHODS This nationwide population-based cohort study was conducted using data obtained from the Taiwan National Health Insurance Database from 2000 to 2011. A total of 10,361 female patients with thyroid cancer (3,292 did not receive (131)I treatment and 7,069 received (131)I treatment) were enrolled, and 41,444 female controls were frequency-matched to the thyroid cancer patients in a 1:4 ratio by age (5-y age group). A Cox proportional hazards model was applied to estimate the risk of breast cancer in thyroid cancer patients receiving or not receiving (131)I treatment in terms of hazard ratios and 95% and 98% confidence intervals. RESULTS The incidence rates of breast cancer in patients with thyroid cancer receiving (131)I therapy, those not receiving (131)I therapy, and controls were 18.9, 17.7, and 13.1 per 10,000 person-years, respectively. Compared with patients with thyroid cancer treated with a cumulative (131)I dose of 4.44 GBq or less, the risk of breast cancer was not significantly increased in those treated with a cumulative (131)I dose of more than 4.44 GBq (adjusted hazard ratio, 0.78; 95% confidence interval, 0.50-1.21, P = 0.26; 98% confidence interval, 0.45-1.33, P > 0.02). CONCLUSION The greatest increased risk of breast cancer in patients with thyroid cancer is associated with the fact that the patient has thyroid cancer regardless of (131)I administration. However, (131)I further increased that risk but not as much as just having thyroid cancer.
Collapse
Affiliation(s)
- Chun-Yi Lin
- Department of Nuclear Medicine, Show Chwan Memorial Hospital, Changhua, Taiwan Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan
| | - Cheng-Li Lin
- Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan College of Medicine, China Medical University, Taichung, Taiwan
| | - Wen-Sheng Huang
- Department of Nuclear Medicine, Changhua Christian Hospital, Changhua, and Taipei Veterans General Hospital, Taipei, Taiwan
| | - Chia-Hung Kao
- Graduate Institute of Clinical Medical Science and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan; and Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan
| |
Collapse
|
15
|
Olthof DC, Bun RJ, Dutrieux RP, Houdijk APJ. An unexpected finding in the resection specimen of a carcinoma of the oral cavity: A case report. Int J Surg Case Rep 2015; 19:55-9. [PMID: 26710330 PMCID: PMC4756081 DOI: 10.1016/j.ijscr.2015.12.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Revised: 12/01/2015] [Accepted: 12/13/2015] [Indexed: 11/11/2022] Open
Abstract
The occurrence of two synchronous, primary cancers is rare. Thyroid carcinoma is incidentally found in the resection specimen after surgery for head and neck cancer in 0.3–1.9% of the patients. A papillary thyroid carcinoma was found coincidentally in lymph nodes recovered after a ‘commando’ procedure for carcinoma of the oral cavity. A tailor made therapeutic approach of incidental thyroid gland carcinoma in head and neck cancer depends on prognosis and life expectancy.
Introduction The occurrence of two synchronous, primary cancers is rare. Thyroid carcinoma is incidentally found in the resection specimen after surgery for head and neck cancer in 0.3–1.9% of the patients. Presentation of case In this report, we describe the case of a 72-year-old patient in whom a primary (synchronous) papillary thyroid carcinoma was found coincidentally upon pathologic examination of lymph nodes recovered from the cervical neck lymph node dissection specimen after a ‘commando’ procedure for carcinoma of the oral cavity. Discussion and conclusion There is no gold standard concerning treatment of the incidentally discovered thyroid gland carcinoma. The decision to perform surgery depends on the life expectancy of the patient, whether the thyroid gland demonstrates clinical or radiologic lesions, the already completed treatment for the head and neck cancer and should always be adjusted to the specific patient.
Collapse
Affiliation(s)
- D C Olthof
- Department of Surgery, Medical Center Alkmaar, Postbus 501, 1800 AM Alkmaar, The Netherlands.
| | - R J Bun
- Department of Head and Neck surgery, Medical Center Alkmaar, Postbus 501, 1800 AM Alkmaar, The Netherlands.
| | - R P Dutrieux
- Department of Pathology, Medical Center Alkmaar, Postbus 501, 1800 AM Alkmaar, The Netherlands.
| | - A P J Houdijk
- Department of Surgery, Medical Center Alkmaar, Postbus 501, 1800 AM Alkmaar, The Netherlands; Trial Center Holland Health, Alkmaar, The Netherlands.
| |
Collapse
|
16
|
Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer. Sci Rep 2015; 5:16129. [PMID: 26530882 PMCID: PMC4632085 DOI: 10.1038/srep16129] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 10/08/2015] [Indexed: 01/13/2023] Open
Abstract
Some studies have demonstrated that familial non-medullary thyroid cancer (FNMTC) has a more aggressive clinical behavior compared to sporadic NMTC (SNMTC). However, FNMTC is difficult to differentiate from SNMTC by the morphology and immunohistochemistry. Although genes responsible for FNMTC were unclear, screening for rare germline mutations on known important tumor suppressor genes might offer more insights on predicting susceptibility to FNMTC. Here, a customized panel was designed to capture all exons of 31 cancer susceptive genes possibly related to FNMTC. Using next-generation sequencing we performed deep sequencing to achieve 500× coverage of the targeted regions. At the end 45 variants were identified in 29 of 47 familial patients and 6 of 16 sporadic patients. Notably, several germline mutations were found matching between paired FNMTC patients from the same family, including APC L292F and A2778S, BRAF D22N, MSH6 G355S and A36V, MSH2 L719F, MEN1 G508D, BRCA1 SS955S, BRCA2 G2508S, and a GNAS inframe insertion. We demonstrated a novel approach to help diagnose and elucidate the genetic cause of the FNMTC patients, and assess whether their family members are exposed to a higher genetic risk. The findings would also provide insights on monitoring the potential second cancers for thyroid cancer patients.
Collapse
|
17
|
Ahn HY, Min HS, Yeo Y, Ma SH, Hwang Y, An JH, Choi HS, Keam B, Im SA, Park DJ, Park IA, Noh DY, Youn YK, Chung JK, Cho BY, Park SK, Park YJ. Radioactive Iodine Therapy Did Not Significantly Increase the Incidence and Recurrence of Subsequent Breast Cancer. J Clin Endocrinol Metab 2015; 100:3486-93. [PMID: 26147607 DOI: 10.1210/jc.2014-2896] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
CONTEXT Previous studies on the extent to which radioactive iodine (RAI) therapy for thyroid cancer increases the risk of subsequently developing breast cancer have given conflicting results. OBJECTIVE This study aimed to evaluate the effect of RAI treatment on breast cancer development and recurrence among female patients with primary thyroid cancer. DESIGN This was a retrospective cohort study. The risk of subsequent breast cancer associated with RAI and its dose in hazard ratios (HRs) with 95% confidential intervals (CIs) were calculated using time-dependent Cox proportional hazard models. PATIENTS A total of 6150 patients with thyroid cancer enrolled between 1973 and 2009 were followed until December 2012. Of these, 3631 (59.0%) received RAI therapy. During the follow-up period, 99 primary breast cancers were diagnosed. MAIN OUTCOME MEASURE Risk of breast cancer development according to RAI therapy and RAI dose during treatment for primary thyroid cancer. RESULTS RAI therapy did not significantly increase the incidence of subsequent breast cancer among female patients (hazard ratio [HR], 0.49; 95% confidence interval [CI], 0.22-1.06) when a 2-year latency period was accounted for. High-dose RAI (≥120 mCi) was associated with a reduced incidence of subsequent breast cancer (HR, 0.17; 95% CI, 0.05-0.62) in the cohort with a 2-year latency period. CONCLUSIONS The long-term follow-up results of this study suggest that RAI treatment for patients with thyroid cancer may not increase the risk or recurrence of breast cancer.
Collapse
Affiliation(s)
- Hwa Young Ahn
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Hye Sook Min
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Yohwan Yeo
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Seung Hyun Ma
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Yunji Hwang
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Jee Hyun An
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Hoon Sung Choi
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Bhumsuk Keam
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Seock-Ah Im
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Do Joon Park
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - In Ae Park
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Dong-Young Noh
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Yeo-Kyu Youn
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - June-Key Chung
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Bo Youn Cho
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Sue K Park
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| | - Young Joo Park
- Departments of Internal Medicine (H.Y.A., J.H.A., H.S.C., B.K., S.-A.I., D.J.P., Y.J.P.), Pathology (H.S.M., I.A.E.), Preventive Medicine (Y.Y., S.H.M., Y.H., S.K.P.), Surgery (D.-Y.N., Y.-K.Y.), and Nuclear Medicine (J.-K.C.), Seoul National University College of Medicine, Seoul, Republic of Korea 110-744; Department of Internal Medicine (H.Y.A.), Seoul National University Bundang Hospital, Seongnam, Republic of Korea 463-707; Department of Internal Medicine (H.Y.A., B.Y.C.), Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Republic of Korea 156-755; Department of Biomedical Science (Y.H., S.K.P.), Seoul National University Graduate School, Seoul, Republic of Korea 110-744; Cancer Research Institute (Y.H., D.-Y.N., S.K.P.), Seoul National University, Seoul, Republic of Korea 110-744; and Department of Internal Medicine (H.S.C.), Kangwon National University School of Medicine, Chuncheon, Republic of Korea 200-722
| |
Collapse
|
18
|
Joseph KR, Edirimanne S, Eslick GD. The association between breast cancer and thyroid cancer: a meta-analysis. Breast Cancer Res Treat 2015; 152:173-181. [PMID: 26058757 DOI: 10.1007/s10549-015-3456-6] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2015] [Accepted: 06/05/2015] [Indexed: 01/02/2023]
Abstract
Previous studies have suggested an association between breast cancer and thyroid cancer; however, there has not been a formal meta-analysis which collates the existing evidence supporting the hypothesis that breast cancer or thyroid cancer predisposes an individual to developing the other. A systematic search was carried out using PubMed and Medline. We searched for articles containing epidemiological evidence of breast cancer following thyroid cancer and vice versa. Additionally, we searched for articles that included epidemiological data involving the incidence of all second primary malignancies (SPMs) following both breast cancer and thyroid cancer, and compared the datasets. The meta-analysis performed in a total of 18 studies showed that there is a significantly increased risk of developing thyroid cancer as a second primary malignancy of breast cancer (SIR = 1.59, 95 % confidence interval (CI) 1.28-1.99). Additionally, there was marginally increased risk of developing breast cancer as a second primary malignancy of thyroid cancer (SIR = 1.24, 95 % CI 1.16-1.33), compared to the general risk of developing a second primary malignancy following thyroid cancer. The findings suggest that the risk of developing thyroid cancer as a second primary malignancy of breast cancer and vice versa is increased compared to the background risk of developing other SPMs. The risk of developing thyroid cancer after a primary breast cancer was higher than the risk of developing breast cancer as a second primary malignancy of thyroid cancer. This suggests that the effects of treatment-related factors and specific pathological processes of each cancer may contribute to the increased risk rather than common risk factors including genetic factors. Elucidation of the common mechanisms between breast cancer and thyroid cancer will have important implications in both diagnostic and therapeutic management of these cancers. Benefit of thyroid ultrasound screening after breast cancer surgery needs to be assessed.
Collapse
Affiliation(s)
- Kyle R Joseph
- The Whiteley-Martin Research Centre, The Discipline of Surgery, Sydney Medical School, Nepean Hospital, The University of Sydney, Clinical Building, Level 3, Penrith, NSW, 2751, Australia
| | - Senarath Edirimanne
- The Whiteley-Martin Research Centre, The Discipline of Surgery, Sydney Medical School, Nepean Hospital, The University of Sydney, Clinical Building, Level 3, Penrith, NSW, 2751, Australia
| | - Guy D Eslick
- The Whiteley-Martin Research Centre, The Discipline of Surgery, Sydney Medical School, Nepean Hospital, The University of Sydney, Clinical Building, Level 3, Penrith, NSW, 2751, Australia.
| |
Collapse
|